Hanmi seeks to gain on Wegovy with its own weight-loss drug
Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press conference held in San Francisco, California, on Jan. 15. [LEE JAE-LIM] SAN FRANCISCO — Hanmi Pharmaceutical aims to disrupt the obesity drug market currently led by Eli Lilly and Novo Nordisk with its own diverse range of weight-loss treatments tailored to meet the unique needs of patients,
'Probably going to be the most prescribed drug'; The future of weight loss drugs
Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.
How weight-loss drugs will impact restaurants
The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Scientist issues weight loss jab warning and says 'should be taken for life'
Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...
Medicine Buffalo2d
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Polls On Weight Loss And Will Power
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
The Next Web5d
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
valuepenguin2d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price or $325 per month after insurance. Find Cheap Health Insurance Quotes in Your Area Weight ...
What you need to know before considering weight loss jabs
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
FOX News on MSN10d
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
With approximately 70% of American adults meeting the criteria for being obese or overweight, more people are turning to ...
Hosted on MSN2d
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss market
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for effective weight-loss drugs.